Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Servier's Shire Oncology Buy Gives Base For US Expansion

Executive Summary

With the $2.4bn acquisition of Shire's oncology assets, including Oncaspar and Onivyde, the French drug maker has laid down a marker to become a key player in cancer and sees the US in particular as the land of opportunity.

Advertisement

Related Content

Servier To Tackle Parkinson's With Oncodesign Pact
Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma
CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
Lonsurf Hits Phase III OS Target In Gastric Cancer Study
Takeda Poised To Move Into Pharma Top 10 With Shire Combination
Takeda Grabs Shire At Last After Long Pursuit
Takeda, Shire Finally Seal £46bn Deal
Servier Acquires Shire Oncology Business For $2.4bn
Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
'We Jumped' At Opportunity To Take On Pfizer's CAR-T Program, Allogene's Chang Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC122902

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel